Skip to main content
Premium Trial:

Request an Annual Quote

GPC Biotech Forms Proteomics Alliance with Aventis Pharma

NEW YORK, Dec 15 - GPC Biotech of Munich and Aventis announced a proteomics
collaboration Friday, in which GPC will use its Pathcode protein interaction
mapping technology to find and validate compounds that interact with a drug
target Aventis has previously identified.

The parties did not disclose the financial terms of the agreement.

This collaboration follows two other joint projects between GPC and Aventis,
one in which GPC used Pathcode to discover new antifungal targets and
another three-year project in which the companies are using genomics and
proteomics technology to identify and validate osteoarthritis drug targets.

Pathcode detects protein-protein interactions using yeast hybrid cells and
is designed to run in a high-throughput manner. GPC Biotech also offers
other proteomic and genomic technologies, such as its Reverse Genomics
cell-based screens of drug targets, to pharma and biotech companies.

In addition to Aventis, GPC also has deals with Bayer, Dupont, Boehringer
Ingelheim, Altana, Cell Genesys, Maxim Pharmaceuticals, Evotec Biosystems,
Morphosys and Karo Bio USA.

The Scan

Self-Reported Hearing Loss in Older Adults Begins Very Early in Life, Study Says

A JAMA Otolaryngology — Head & Neck Surgery study says polygenic risk scores associated with hearing loss in older adults is also associated with hearing decline in younger groups.

Genome-Wide Analysis Sheds Light on Genetics of ADHD

A genome-wide association study meta-analysis of attention-deficit hyperactivity disorder appearing in Nature Genetics links 76 genes to risk of having the disorder.

MicroRNA Cotargeting Linked to Lupus

A mouse-based study appearing in BMC Biology implicates two microRNAs with overlapping target sites in lupus.

Enzyme Involved in Lipid Metabolism Linked to Mutational Signatures

In Nature Genetics, a Wellcome Sanger Institute-led team found that APOBEC1 may contribute to the development of the SBS2 and SBS13 mutational signatures in the small intestine.